Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6401362 | 0.91 | RAB9A (0.45) | NPC1RAB9ASIGMAR1HPGDOPRK1 | |
| SCHEMBL6403180 | 0.89 | MMP3 (0.42) | NPC1RAB9ALMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL6405210 | 0.87 | NPC1 (0.43) | NPC1RAB9ASIGMAR1OPRK1OPRM1 | |
| SCHEMBL6409458 | 0.87 | NPC1 (0.42) | NPC1RAB9ASIGMAR1HPGDOPRK1 | |
| SCHEMBL6407167 | 0.85 | CA1 (0.42) | NPC1RAB9ALMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL6401375 | 0.84 | NPC1 (0.39) | NPC1RAB9ASIGMAR1LMNAALDH1A1 | |
| SCHEMBL6404812 | 0.83 | NPC1 (0.40) | NPC1RAB9ASIGMAR1HPGDOPRK1 | |
| SCHEMBL6409464 | 0.81 | ALOX5 (0.42) | ALDH1A1LIMK2 | |
| SCHEMBL6402831 | 0.81 | OPRK1 (0.45) | NPC1RAB9ASIGMAR1HPGDOPRK1 | |
| SCHEMBL6402653 | 0.80 | CTSS (0.47) | NPC1RAB9ASIGMAR1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900237-B2 | Sulfonamide compounds as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | claimed |
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | Celera Corporation | 2003-08-21 | — | — | US | claimed |
| US-6900237-B2 | Sulfonamide compounds as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | Celera Corporation | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | PRSS1, PRSS3, SPINT2 | NPC1 972/4885RAB9A 2791/4885SIGMAR1 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.